A clinical diagnosis of Alzheimer's disease dementia (ADD) encompasses considerable
pathological and clinical heterogeneity. While Alzheimer's disease patients typically show a …

Abstract Background [18F] FDG-PET hypometabolism patterns are indicative of different
neurodegenerative conditions, even from the earliest disease phase. This makes [18F] FDG …

ABSTRACT BACKGROUND Posterior cortical atrophy (PCA) is a rare neurodegenerative
syndrome with visuospatial deficits. PET studies have identified hypometabolism of the …

Background Subjects with amnesic mild cognitive impairment (aMCI) may include patients at
high risk for progression to Alzheimer disease (AD) and a population with different …

Background: It is not known yet whether temporoparietal glucose hypometabolism in
patients with probable Alzheimer's disease (AD) reflects disease severity or different …

Objectives It is well known that Alzheimer's disease (AD)‐type pathology is commonly
present in dementia with Lewy bodies (DLB) brains and that the degree of AD‐type …

BACKGROUND AND PURPOSE: Decreased glucose metabolism in the temporal and
parietal lobes on FDG-PET is recognized as an early imaging marker for the AD pathology …

Background Previous publications indicate that Alzheimer's Disease (AD) related cortical
atrophy may develop in asymmetric patterns, with accentuation of the left hemisphere. Since …

The early diagnostic value of glucose hypometabolism and atrophy as potential
neuroimaging biomarkers of mild cognitive impairment (MCI) and Alzheimer's disease (AD) …

Purpose:[18F] fluorodeoxyglucose (FDG) PET imaging of the brain can be used to assist in
the differential diagnosis of dementia. Group differences in glucose uptake between patients …